74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Abeona Therapeutics Inc
Closed
4.8 -5.7
Overview
Share price change
24h
Min
4.8
Max
4.85
P/E Sector Avg | 8.473 37.003 |
|---|---|
Employees | 136 |
Recommendations | Buy |
|---|---|
12 Months Forecast | +315.8% upside |
Next Earnings | 12 Nov 2025 |
|---|
Market Cap | -35M 241M |
|---|---|
Previous open | 10.5 |
Previous close | 4.8 |
Abeona Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Abeona Therapeutics Inc Forecast
Price Target
By TipRanks
315.8% upside
12 Months Forecast
Average 20 USD 315.8%
High 20 USD
Low 20 USD
Based on 2 Wall Street analysts offering 12 month price targets forAbeona Therapeutics Inc - Dist in the last 3 months.
Financials
$
About Abeona Therapeutics Inc
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.
Live chat